rivastigmine Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
acetylcholinesterase inhibitors 2392 123441-03-2

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • prometax
  • rivastigmine
  • S-Rivastigmine
  • rivastigmine tartrate
  • rivastigmine hydrogen tartrate
  • rivastigmine hexal
  • exelon
A carbamate-derived reversible CHOLINESTERASE INHIBITOR that is selective for the CENTRAL NERVOUS SYSTEM and is used for the treatment of DEMENTIA in ALZHEIMER DISEASE and PARKINSON DISEASE.
  • Molecular weight: 250.34
  • Formula: C14H22N2O2
  • CLOGP: 2.10
  • LIPINSKI: 0
  • HAC: 4
  • HDO: 0
  • TPSA: 32.78
  • ALOGS: -2.09
  • ROTB: 5

  • Status: OFP

  • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
9 mg O
9.50 mg TD

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 0.10 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 0.80 ┬ÁM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 72 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 1.30 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 12 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.60 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 1.40 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
May 12, 1998 EMA
April 21, 2000 FDA NOVARTIS

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Product adhesion issue 421.72 17.30 129 17705 5368 53325864
Application site erythema 358.96 17.30 112 17722 4979 53326253
Dementia 313.54 17.30 139 17695 16611 53314621
Hallucination 310.26 17.30 204 17630 53634 53277598
Application site pruritus 266.40 17.30 85 17749 4064 53327168
Fall 263.03 17.30 446 17388 357994 52973238
Death 205.18 17.30 400 17434 356832 52974400
Confusional state 188.14 17.30 275 17559 193946 53137286
Application site rash 155.80 17.30 51 17783 2645 53328587
Agitation 155.28 17.30 140 17694 58486 53272746
Hallucination, visual 134.94 17.30 82 17752 18750 53312482
Disorientation 132.77 17.30 108 17726 39251 53291981
Aggression 128.16 17.30 86 17748 23317 53307915
Application site hypersensitivity 113.94 17.30 24 17810 206 53331026
Cognitive disorder 107.00 17.30 101 17733 44677 53286555
Memory impairment 105.99 17.30 136 17698 84621 53246611
Abnormal behaviour 104.74 17.30 74 17760 21792 53309440
Blood cholinesterase decreased 99.57 17.30 20 17814 132 53331100
Wrong technique in product usage process 95.74 17.30 109 17725 59923 53271309
On and off phenomenon 91.85 17.30 34 17800 2544 53328688
Rheumatoid arthritis 91.77 17.30 3 17831 314528 53016704
Delusion 90.44 17.30 54 17780 11955 53319277
Bradycardia 85.66 17.30 112 17722 70944 53260288
Product administration error 80.96 17.30 63 17771 21468 53309764
Arthralgia 76.38 17.30 26 17808 439757 52891475
Application site reaction 75.93 17.30 22 17812 755 53330477
Application site irritation 75.40 17.30 27 17807 1837 53329395
Mini mental status examination abnormal 74.39 17.30 11 17823 3 53331229
Stoma site discharge 72.82 17.30 28 17806 2326 53328906
Bradykinesia 71.49 17.30 33 17801 4320 53326912
Dementia Alzheimer's type 70.60 17.30 23 17811 1174 53330058
Dyskinesia 68.86 17.30 68 17766 31765 53299467
Lack of application site rotation 67.42 17.30 10 17824 3 53331229
Syncope 65.79 17.30 127 17707 111866 53219366
Restlessness 64.50 17.30 62 17772 28025 53303207
Cerebral atrophy 64.14 17.30 32 17802 4972 53326260
Dysphagia 61.37 17.30 105 17729 84292 53246940
Pain 61.34 17.30 64 17770 588334 52742898
Cholinergic syndrome 60.89 17.30 16 17818 379 53330853
Speech disorder 58.84 17.30 69 17765 39112 53292120
Delirium 55.74 17.30 69 17765 41360 53289872
Vomiting 55.20 17.30 318 17516 496821 52834411
Femur fracture 54.99 17.30 67 17767 39518 53291714
Drug hypersensitivity 54.88 17.30 11 17823 265231 53066001
Alopecia 54.65 17.30 7 17827 234576 53096656
Tremor 54.56 17.30 126 17708 125610 53205622
Dementia with Lewy bodies 53.92 17.30 14 17820 316 53330916
Skin irritation 53.69 17.30 34 17800 8350 53322882
Loss of consciousness 53.51 17.30 118 17716 114094 53217138
Cerebrovascular accident 53.09 17.30 112 17722 105062 53226170
Freezing phenomenon 52.18 17.30 20 17814 1647 53329585
Pneumonia aspiration 50.83 17.30 60 17774 34241 53296991
Stoma site erythema 50.22 17.30 19 17815 1510 53329722
Akinesia 48.93 17.30 20 17814 1951 53329281
Muscle rigidity 48.02 17.30 35 17799 10806 53320426
Gait inability 47.09 17.30 61 17773 38250 53292982
Marasmus 46.80 17.30 14 17820 538 53330694
Malaise 46.52 17.30 239 17595 357378 52973854
Decreased appetite 45.94 17.30 167 17667 214807 53116425
Product administration interrupted 45.15 17.30 15 17819 814 53330418
Somnolence 44.37 17.30 140 17694 167594 53163638
Joint swelling 44.03 17.30 12 17822 234626 53096606
Femoral neck fracture 43.95 17.30 30 17804 8353 53322879
Dysstasia 43.54 17.30 42 17792 19057 53312175
General physical health deterioration 42.93 17.30 127 17707 146815 53184417
Accessory cardiac pathway 38.39 17.30 6 17828 5 53331227
Infusion related reaction 37.93 17.30 4 17830 155953 53175279
Gait disturbance 37.88 17.30 128 17706 158714 53172518
Application site discolouration 37.56 17.30 13 17821 800 53330432
Sinusitis 36.98 17.30 6 17828 168558 53162674
Subileus 36.65 17.30 19 17815 3197 53328035
Fatigue 36.57 17.30 124 17710 730382 52600850
Eating disorder 35.76 17.30 35 17799 16162 53315070
Swelling 35.42 17.30 10 17824 191095 53140137
Product prescribing error 35.30 17.30 41 17793 22990 53308242
Dehydration 35.25 17.30 130 17704 168280 53162952
Application site dermatitis 34.30 17.30 9 17825 212 53331020
Concomitant disease aggravated 33.78 17.30 26 17808 8712 53322520
Application site swelling 33.73 17.30 11 17823 563 53330669
Abnormal dreams 33.44 17.30 28 17806 10573 53320659
Dyspnoea 33.21 17.30 94 17740 586138 52745094
Completed suicide 32.46 17.30 4 17830 138197 53193035
Hypokinesia 32.27 17.30 30 17804 12997 53318235
Vascular encephalopathy 32.01 17.30 10 17824 445 53330787
Hyperkinesia 31.91 17.30 15 17819 2045 53329187
Extrapyramidal disorder 31.57 17.30 29 17805 12373 53318859
Arthropathy 31.10 17.30 5 17829 141448 53189784
Fracture 30.89 17.30 34 17800 17985 53313247
Pleurothotonus 30.88 17.30 13 17821 1366 53329866
Pain in extremity 30.74 17.30 30 17804 285020 53046212
Posture abnormal 30.07 17.30 15 17819 2328 53328904
Orthostatic hypotension 29.93 17.30 43 17791 29710 53301522
Off label use 28.76 17.30 73 17761 472139 52859093
Arrhythmia 28.35 17.30 47 17787 36732 53294500
Screaming 28.00 17.30 16 17818 3261 53327971
Drug ineffective 27.96 17.30 160 17674 817085 52514147
Back pain 27.21 17.30 23 17811 234224 53097008
Balance disorder 27.05 17.30 69 17765 73138 53258094
Neutropenia 26.55 17.30 10 17824 159175 53172057
Parkinson's disease 26.37 17.30 12 17822 1519 53329713
Headache 26.20 17.30 92 17742 536729 52794503
Aphasia 26.00 17.30 41 17793 30737 53300495
Vascular dementia 25.89 17.30 9 17825 561 53330671
Weight decreased 25.09 17.30 149 17685 234799 53096433
Dermatitis contact 24.89 17.30 22 17812 8930 53322302
Unresponsive to stimuli 24.81 17.30 42 17792 33384 53297848
Febrile neutropenia 24.73 17.30 3 17831 104933 53226299
Senile dementia 24.57 17.30 7 17827 226 53331006
Apparent death 24.49 17.30 11 17823 1351 53329881
Pemphigus 24.45 17.30 3 17831 104028 53227204
Cough 24.41 17.30 30 17804 256863 53074369
Urinary retention 24.15 17.30 38 17796 28428 53302804
Psychotic symptom 23.55 17.30 10 17824 1073 53330159
Application site vesicles 23.52 17.30 11 17823 1483 53329749
Resting tremor 23.15 17.30 9 17825 770 53330462
Hip fracture 22.98 17.30 37 17797 28220 53303012
Nightmare 22.96 17.30 29 17805 17722 53313510
Product administered at inappropriate site 22.94 17.30 13 17821 2609 53328623
Parkinsonism 22.80 17.30 21 17813 8992 53322240
Psychotic disorder 22.73 17.30 34 17800 24351 53306881
Agnosia 22.68 17.30 6 17828 146 53331086
Depressed level of consciousness 21.89 17.30 53 17781 54375 53276857
Stoma site irritation 21.64 17.30 7 17827 349 53330883
Paraesthesia 21.28 17.30 8 17826 127507 53203725
Myalgia 21.25 17.30 9 17825 133482 53197750
Dizziness 20.47 17.30 202 17632 372057 52959175
Faecaloma 20.45 17.30 19 17815 8222 53323010
Stomatitis 20.42 17.30 4 17830 98154 53233078
Paranoia 20.35 17.30 22 17812 11402 53319830
Neuropathy peripheral 19.86 17.30 5 17829 103182 53228050
Stoma site inflammation 19.85 17.30 8 17826 752 53330480
Platelet count decreased 19.39 17.30 6 17828 108093 53223139
Arthritis 19.38 17.30 3 17831 87295 53243937
Pyrexia 19.04 17.30 70 17764 403123 52928109
Nasopharyngitis 18.74 17.30 22 17812 192273 53138959
Medication error 18.64 17.30 39 17795 36326 53294906
Stoma site pain 18.48 17.30 9 17825 1327 53329905
Apathy 18.42 17.30 18 17816 8294 53322938
Incorrect product administration duration 18.13 17.30 20 17814 10604 53320628
Rash 17.63 17.30 83 17751 446108 52885124
Peripheral swelling 17.61 17.30 26 17808 206082 53125150
Cerebral haemorrhage 17.56 17.30 34 17800 29962 53301270

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Hallucination 456.92 17.96 293 15074 52326 32445833
Product adhesion issue 401.97 17.96 102 15265 1457 32496702
Confusional state 275.83 17.96 338 15029 142777 32355382
Aggression 266.28 17.96 188 15179 39201 32458958
Application site erythema 259.43 17.96 79 15288 2264 32495895
Dementia 239.87 17.96 120 15247 13266 32484893
Fall 208.45 17.96 349 15018 195852 32302307
Abnormal behaviour 164.21 17.96 120 15247 26346 32471813
Application site pruritus 162.91 17.96 49 15318 1344 32496815
Agitation 144.92 17.96 156 15211 57080 32441079
Cognitive disorder 135.37 17.96 106 15261 25788 32472371
On and off phenomenon 125.57 17.96 51 15316 3450 32494709
Freezing phenomenon 122.51 17.96 45 15322 2318 32495841
Stoma site discharge 119.92 17.96 42 15325 1883 32496276
Hallucination, visual 118.33 17.96 83 15284 17076 32481083
Death 113.29 17.96 416 14951 382101 32116058
Gait disturbance 112.85 17.96 163 15204 80245 32417914
Bradykinesia 106.03 17.96 48 15319 4238 32493921
Application site rash 104.37 17.96 31 15336 813 32497346
Somnolence 97.14 17.96 175 15192 103622 32394537
Stoma site erythema 92.81 17.96 32 15335 1368 32496791
Disorientation 84.32 17.96 91 15276 33334 32464825
Dementia with Lewy bodies 83.97 17.96 25 15342 661 32497498
Blood cholinesterase decreased 83.64 17.96 18 15349 117 32498042
Memory impairment 83.07 17.96 99 15268 40380 32457779
Muscle rigidity 81.54 17.96 56 15311 11130 32487029
General physical health deterioration 80.68 17.96 172 15195 115087 32383072
Akinesia 76.45 17.96 33 15334 2600 32495559
Pneumonia aspiration 75.30 17.96 95 15272 41061 32457098
Delusion 71.37 17.96 55 15312 13053 32485106
Dyskinesia 69.83 17.96 70 15297 23533 32474626
Fibroma 67.17 17.96 20 15347 529 32497630
Restlessness 64.96 17.96 69 15298 24812 32473347
Mobility decreased 64.15 17.96 73 15294 28336 32469823
Device dislocation 63.13 17.96 38 15329 6025 32492134
Delirium 54.13 17.96 84 15283 43962 32454197
Application site irritation 54.08 17.96 18 15349 690 32497469
Dysphagia 54.06 17.96 101 15266 61375 32436784
Speech disorder 51.85 17.96 63 15304 26190 32471969
Gait inability 49.52 17.96 54 15313 19993 32478166
Stoma site reaction 48.39 17.96 14 15353 334 32497825
Stoma site inflammation 48.30 17.96 17 15350 773 32497386
Parkinson's disease 48.04 17.96 21 15346 1705 32496454
Paranoia 47.50 17.96 40 15327 10759 32487400
Reduced facial expression 46.02 17.96 17 15350 889 32497270
Arthralgia 44.92 17.96 8 15359 148440 32349719
Hyperkinesia 42.44 17.96 21 15346 2261 32495898
Tremor 42.21 17.96 108 15259 81169 32416990
Febrile neutropenia 42.01 17.96 4 15363 119562 32378597
Syncope 40.00 17.96 113 15254 90011 32408148
Prescribed underdose 40.00 17.96 33 15334 8626 32489533
Application site discolouration 39.53 17.96 11 15356 227 32497932
Sinus bradycardia 39.41 17.96 39 15328 12899 32485260
Neutropenia 38.25 17.96 10 15357 142165 32355994
Urinary incontinence 38.09 17.96 45 15322 18162 32479997
Abnormal dreams 36.18 17.96 31 15336 8533 32489626
Hangover 35.97 17.96 15 15352 1084 32497075
Application site hypersensitivity 35.88 17.96 9 15358 122 32498037
Product administration error 35.00 17.96 40 15327 15585 32482574
Mini mental status examination abnormal 34.07 17.96 6 15361 10 32498149
Dementia Alzheimer's type 32.77 17.96 11 15356 433 32497726
Marasmus 32.49 17.96 12 15355 627 32497532
Balance disorder 32.40 17.96 63 15304 39396 32458763
Parkinsonism 32.26 17.96 28 15339 7841 32490318
Condition aggravated 32.07 17.96 152 15215 155509 32342650
Bradycardia 32.01 17.96 90 15277 71472 32426687
Motor dysfunction 30.51 17.96 25 15342 6471 32491688
Acute kidney injury 30.35 17.96 58 15309 293410 32204749
Sleep disorder 30.07 17.96 49 15318 26703 32471456
Nonspecific reaction 30.06 17.96 14 15353 1318 32496841
Psychotic disorder 29.81 17.96 45 15322 22975 32475184
Therapeutic product effect variable 29.51 17.96 16 15351 2080 32496079
Application site reaction 28.74 17.96 10 15357 439 32497720
Urinary tract infection 28.56 17.96 93 15274 79978 32418181
Dyspnoea 28.32 17.96 83 15284 361962 32136197
Malaise 28.20 17.96 161 15206 176977 32321182
Stoma site infection 28.01 17.96 13 15354 1214 32496945
Stoma site pain 27.89 17.96 12 15355 937 32497222
Stoma site extravasation 27.14 17.96 8 15359 204 32497955
Dysstasia 26.73 17.96 30 15337 11456 32486703
Screaming 26.26 17.96 13 15354 1401 32496758
Tension 26.00 17.96 15 15352 2198 32495961
Application site vesicles 25.95 17.96 10 15357 588 32497571
Intentional medical device removal by patient 25.38 17.96 9 15358 418 32497741
Stoma site hypergranulation 25.34 17.96 9 15358 420 32497739
White blood cell count decreased 25.32 17.96 6 15361 91192 32406967
Device kink 25.06 17.96 10 15357 645 32497514
Hypokinesia 24.97 17.96 25 15342 8380 32489779
Neuroleptic malignant syndrome 23.79 17.96 35 15332 17460 32480699
Pancytopenia 23.44 17.96 7 15360 91228 32406931
Disturbance in attention 23.36 17.96 41 15326 23712 32474447
Myalgia 23.24 17.96 5 15362 81225 32416934
Incorrect product administration duration 23.02 17.96 18 15349 4360 32493799
Parkinsonian gait 22.90 17.96 9 15358 558 32497601
Platelet count decreased 22.66 17.96 13 15354 114578 32383581
Hypersomnia 22.47 17.96 28 15339 11933 32486226
Miosis 22.46 17.96 24 15343 8680 32489479
Orthostatic hypotension 22.34 17.96 42 15325 25608 32472551
Salivary hypersecretion 22.11 17.96 23 15344 8065 32490094
Underdose 22.04 17.96 29 15338 13040 32485119
Drug dispensed to wrong patient 21.89 17.96 7 15360 236 32497923
Apathy 21.87 17.96 21 15346 6694 32491465
Aphasia 21.86 17.96 37 15330 20791 32477368
Loss of consciousness 21.77 17.96 87 15280 82620 32415539
Concomitant disease progression 21.40 17.96 14 15353 2564 32495595
Pain 21.21 17.96 35 15332 187521 32310638
Oesophageal dilatation 20.70 17.96 6 15361 144 32498015
Amnesia 20.58 17.96 40 15327 24996 32473163
Headache 20.05 17.96 39 15328 196158 32302001
Skin irritation 19.42 17.96 17 15350 4814 32493345
Middle insomnia 18.74 17.96 19 15348 6465 32491694
Psychomotor hyperactivity 18.34 17.96 22 15345 9017 32489142
Stoma site odour 18.21 17.96 5 15362 98 32498061
Dyschezia 18.20 17.96 10 15357 1334 32496825
Urinary retention 18.05 17.96 47 15320 35650 32462509

Pharmacologic Action:

SourceCodeDescription
ATC N06DA03 NERVOUS SYSTEM
PSYCHOANALEPTICS
ANTI-DEMENTIA DRUGS
Anticholinesterases
FDA MoA N0000000177 Cholinesterase Inhibitors
MeSH PA D002491 Central Nervous System Agents
MeSH PA D018678 Cholinergic Agents
MeSH PA D002800 Cholinesterase Inhibitors
MeSH PA D004791 Enzyme Inhibitors
MeSH PA D018696 Neuroprotective Agents
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D020011 Protective Agents
CHEBI has role CHEBI:37733 BChE inhibitor
CHEBI has role CHEBI:38323 cholinergic agent
CHEBI has role CHEBI:63726 neuroprotective agents
FDA EPC N0000175723 Cholinesterase Inhibitor

Drug Use (View source of the data)

DiseaseRelationSNOMED_IDDOID
Alzheimer's disease indication 26929004 DOID:10652
Dementia associated with Parkinson's Disease indication 425390006
Diffuse Lewy body disease off-label use 80098002
Moderate to Severe Alzheimer's Type Dementia off-label use
Urinary tract obstruction contraindication 7163005 DOID:5200
Chronic obstructive lung disease contraindication 13645005 DOID:3083
Parkinsonism contraindication 32798002
Sick sinus syndrome contraindication 36083008 DOID:13884
Gastrointestinal ulcer contraindication 40845000
Conduction disorder of the heart contraindication 44808001
Neuromuscular block, function contraindication 55394004
Anorexia nervosa contraindication 56882008 DOID:8689
Diarrhea contraindication 62315008
Gastrointestinal hemorrhage contraindication 74474003
Extrapyramidal disease contraindication 76349003
Weight loss contraindication 89362005
Seizure disorder contraindication 128613002
Asthma contraindication 195967001 DOID:2841
Atrioventricular block contraindication 233917008 DOID:0050820
Vomiting contraindication 422400008
Nausea contraindication 422587007

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 8.32 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])
Mechanism
action
Bioact sourceMoA source
Acetylcholinesterase Enzyme INHIBITOR IC50 7.43 CHEMBL IUPHAR
Cholinesterase Enzyme INHIBITOR IC50 7.52 CHEMBL IUPHAR
Acetylcholinesterase Enzyme IC50 5.95 CHEMBL
Butyrylcholinesterase; Protein Bche Enzyme IC50 6.46 CHEMBL
Acetylcholinesterase Enzyme IC50 5.74 CHEMBL
Acetylcholinesterase Enzyme IC50 5.38 CHEMBL
Acetylcholinesterase Enzyme IC50 6.21 CHEMBL
Cholinesterase Enzyme IC50 5.80 CHEMBL
Butyrylcholinesterase Enzyme IC50 6.80 CHEMBL
Cholinesterase Enzyme IC50 6.08 CHEMBL
Acetylcholine receptor subunit epsilon Ion channel IC50 5.05 CHEMBL
Cholinesterase Enzyme IC50 5.20 CHEMBL

External reference:

IDSource
4021219 VUID
N0000148665 NUI
D03822 KEGG_DRUG
129101-54-8 SECONDARY_CAS_RN
4021219 VANDF
4021220 VANDF
C0649350 UMLSCUI
CHEBI:8874 CHEBI
CHEMBL636 ChEMBL_ID
CHEMBL215645 ChEMBL_ID
DB00989 DRUGBANK_ID
D000068836 MESH_DESCRIPTOR_UI
7562 INN_ID
77991 PUBCHEM_CID
6602 IUPHAR_LIGAND_ID
PKI06M3IW0 UNII
183379 RXNORM
174208 MMSL
23978 MMSL
31947 MMSL
79573 MMSL
8887 MMSL
d04537 MMSL
007559 NDDF
007560 NDDF
126131008 SNOMEDCT_US
323368009 SNOMEDCT_US
395868008 SNOMEDCT_US

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Exelon HUMAN PRESCRIPTION DRUG LABEL 1 0078-0501 PATCH, EXTENDED RELEASE 4.60 mg TRANSDERMAL NDA 30 sections
Exelon HUMAN PRESCRIPTION DRUG LABEL 1 0078-0502 PATCH, EXTENDED RELEASE 9.50 mg TRANSDERMAL NDA 30 sections
Exelon HUMAN PRESCRIPTION DRUG LABEL 1 0078-0503 PATCH, EXTENDED RELEASE 13.30 mg TRANSDERMAL NDA 30 sections
Rivastigmine HUMAN PRESCRIPTION DRUG LABEL 1 0378-9070 PATCH 4.60 mg TRANSDERMAL ANDA 27 sections
Rivastigmine HUMAN PRESCRIPTION DRUG LABEL 1 0378-9071 PATCH 9.50 mg TRANSDERMAL ANDA 27 sections
Rivastigmine HUMAN PRESCRIPTION DRUG LABEL 1 0378-9072 PATCH 13.30 mg TRANSDERMAL ANDA 27 sections
Rivastigmine HUMAN PRESCRIPTION DRUG LABEL 1 0781-7304 PATCH, EXTENDED RELEASE 4.60 mg TRANSDERMAL NDA authorized generic 27 sections
Rivastigmine HUMAN PRESCRIPTION DRUG LABEL 1 0781-7309 PATCH, EXTENDED RELEASE 9.50 mg TRANSDERMAL NDA authorized generic 27 sections
Rivastigmine HUMAN PRESCRIPTION DRUG LABEL 1 0781-7313 PATCH, EXTENDED RELEASE 13.30 mg TRANSDERMAL NDA authorized generic 27 sections
Rivastigmine Tartrate HUMAN PRESCRIPTION DRUG LABEL 1 0904-6587 CAPSULE 1.50 mg ORAL ANDA 24 sections
Rivastigmine Tartrate HUMAN PRESCRIPTION DRUG LABEL 1 0904-7107 CAPSULE 1.50 mg ORAL ANDA 25 sections
Rivastigmine HUMAN PRESCRIPTION DRUG LABEL 1 16714-115 PATCH, EXTENDED RELEASE 4.60 mg TRANSDERMAL ANDA 25 sections
Rivastigmine HUMAN PRESCRIPTION DRUG LABEL 1 16714-116 PATCH, EXTENDED RELEASE 9.50 mg TRANSDERMAL ANDA 25 sections
Rivastigmine HUMAN PRESCRIPTION DRUG LABEL 1 16714-117 PATCH, EXTENDED RELEASE 13.30 mg TRANSDERMAL ANDA 25 sections
Exelon HUMAN PRESCRIPTION DRUG LABEL 1 21695-357 PATCH, EXTENDED RELEASE 4.60 mg TRANSDERMAL NDA 16 sections
RIVASTIGMINE TARTRATE Human Prescription Drug Label 1 27241-090 CAPSULE 1.50 mg ORAL ANDA 25 sections
RIVASTIGMINE TARTRATE Human Prescription Drug Label 1 27241-091 CAPSULE 3 mg ORAL ANDA 25 sections
RIVASTIGMINE TARTRATE Human Prescription Drug Label 1 27241-092 CAPSULE 4.50 mg ORAL ANDA 25 sections
RIVASTIGMINE TARTRATE Human Prescription Drug Label 1 27241-093 CAPSULE 6 mg ORAL ANDA 25 sections
RIVASTIGMINE TARTRATE Human Prescription Drug Label 1 33342-089 CAPSULE 1.50 mg ORAL ANDA 25 sections
RIVASTIGMINE TARTRATE Human Prescription Drug Label 1 33342-090 CAPSULE 3 mg ORAL ANDA 25 sections
RIVASTIGMINE TARTRATE Human Prescription Drug Label 1 33342-091 CAPSULE 4.50 mg ORAL ANDA 25 sections
RIVASTIGMINE TARTRATE Human Prescription Drug Label 1 33342-092 CAPSULE 6 mg ORAL ANDA 25 sections
Rivastigmine Tartrate Human Prescription Drug Label 1 46708-063 CAPSULE 1.50 mg ORAL ANDA 26 sections
Rivastigmine Tartrate Human Prescription Drug Label 1 46708-064 CAPSULE 3 mg ORAL ANDA 26 sections
Rivastigmine Tartrate Human Prescription Drug Label 1 46708-065 CAPSULE 4.50 mg ORAL ANDA 26 sections
Rivastigmine Tartrate Human Prescription Drug Label 1 46708-066 CAPSULE 6 mg ORAL ANDA 26 sections
Rivastigmine Transdermal System HUMAN PRESCRIPTION DRUG LABEL 1 47781-304 PATCH, EXTENDED RELEASE 4.60 mg TRANSDERMAL ANDA 26 sections
Rivastigmine Transdermal System HUMAN PRESCRIPTION DRUG LABEL 1 47781-305 PATCH, EXTENDED RELEASE 9.50 mg TRANSDERMAL ANDA 26 sections
Rivastigmine Transdermal System HUMAN PRESCRIPTION DRUG LABEL 1 47781-405 PATCH, EXTENDED RELEASE 13.30 mg TRANSDERMAL ANDA 26 sections